title: Clinical experience with amphotericin B in acute myelogenous leukemia.
abstract: The empirical use of amphotericin B in febrile leukemic patients not responding to antimicrobial agents has previously led to a significant decrease in fatal fungal infections and a significant increase in complete remissions. In this series of 66 patients receiving induction therapy for acute myelogenous leukemia (AML), 49 (74%) received amphotericin B. The median interval between institution of antibiotics and amphotericin B was ten days. Fifteen patients had clinical evidence of fungal infection, but only two (3%) died of fungal infection during induction therapy for AML. We discontinued amphotericin B upon granulocyte recovery (greater than 500/cu mm) unless a pulmonary infiltrate was present. Even though only five of 15 patients with probable fungal infection received more than 1,000 mg of amphotericin B, no patient had recurrent fungal disease while in remission. The incidence of clinically suspected fungal pneumonia during consolidation therapy and reinduction therapy also suggested that our therapy was adequate. An increased incidence of late fungal pneumonia in patients receiving reinduction was associated with prolonged neutropenia (greater than 50 days). This study supports the empirical use of amphotericin B during induction therapy for AML, and suggests that doses can be smaller than those generally recommended for fungal infection.
authors.forename: R S
authors.initials: RS
authors.lastname: Stein
authors.forename: J P
authors.initials: JP
authors.lastname: Greer
authors.forename: W
authors.initials: W
authors.lastname: Ferrin
authors.forename: R
authors.initials: R
authors.lastname: Lenox
authors.forename: M R
authors.initials: MR
authors.lastname: Baer
authors.forename: J M
authors.initials: JM
authors.lastname: Flexner
mesh_terms: D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001228:Aspergillosis / Q000188:drug therapy; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology; D011014:Pneumonia / Q000188:drug therapy; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D003561:Cytarabine; D000666:Amphotericin B